Reading SNWV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNWV free→Reading SNWV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNWV free→QuarterlyIQ Insights · SNWV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026. As previously announced, a business update via conference call will occur on May 13, 2026 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. On March 26, 2026 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. As previously announced, a business update via conference call will occur on March 27, 2026 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review . In connection with the preparation of the 2025 consolidated financial statements of Sanuwave Health, Inc. (the “Company”), the Company engaged a third party to conduct a sales and use tax nexus study. Management used this third party report and identified that the Company had a historical state sales and use tax liability related to prior periods. The Company is required and subject…
Results of Operations and Financial Condition. On November 7, 2025 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2025. As previously announced, a business update via conference call will occur on November 7, 2025 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on September 25, 2025, Andrew Walko, the former President of Sanuwave Health, Inc. (the “Company”), was terminated without cause, effective as of October 24, 2025 (the “Separation Date”). On the Separation Date, Mr. Walko and the Company entered into a Separation and Release Agreement (the “Separation Agreement”), pursuant…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2025, Daniel Coyle was appointed the Chief Operating Officer of Sanuwave Health, Inc. (the “Company”). Mr. Coyle, age 35, was the Company’s Vice President of Engineering and Operations from October 2024 through September 2025, and a Program Director at Nextern, a medical device manufacturer, from September 2019 through September 20…
Entry into a Material Definitive Agreement. On September 25, 2025, Sanuwave Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as a borrower, Sanuwave, Inc., as a guarantor, SanuWave Services, LLC, as a guarantor, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”). The Credit Agreement provides for a $23.0 million secured term loan (the “Term Loan”) that matures S…
below) and to pay fees and expenses related to the Credit Agreement. Loans made under the Facility will accrue interest at a rate per annum equal to either, at the Company’s option, a term rate based upon the secured overnight financing rate (“SOFR”) plus a margin of 3.50% or base rate (generally determined according to the higher of the prime rate and 2.5%) plus a margin of 2.50%. Interest is payable in arrears, in the case of loans bearing interest based on term SOFR, at the end of the appl…
Creation of a Direct Financial Obligation or an Obligation under an Off- Balance Sheet Arrangement of a Registrant. The information set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed under
Results of Operations and Financial Condition. On August 8, 2025 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2025. As previously announced, a business update via conference call will occur on August 8, 2025 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on May 30, 2025, Nanci Gilmore, the former Chief Commercial Officer of Sanuwave Health, Inc. (the “Company”), was terminated without cause, effective as of the same date. On July 28, 2025, Ms. Gilmore and the Company entered into a Separation and Release Agreement (the “Separation Agreement”), pursuant to which Ms. Gilmore…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 30, 2025, Nanci Gilmore, the Chief Commercial Officer of Sanuwave Health, Inc. (the “Company”), was terminated without cause, effective as of the same date. P ursuant to her offer letter, dated January 11, 2023 (the “Offer Letter”), subject to her execution, delivery and non-revocation of a release of claims and her compliance with the restr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 26, 2025, A. Michael Stolarski, a member of the Board of Directors (the “Board”) of Sanuwave Health, Inc., a Nevada corporation (the “Company”), notified the Company of his decision to resign from the Board, effective May 27, 2025. Mr. Stolarski’s resignation is not a result of any disagreement between him and the Company, its management, th…
Changes in Registrant's Certifying Accountant. Baker Tilly has completed its client acceptance procedures as referenced in the Original Form 8-K, and the Company and Baker Tilly entered into an engagement letter on May 20, 2025. There have been no changes to the disclosures regarding consultations, reports, disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K and the relat…
Changes in Registrant's Certifying Accountant. On May 12, 2025, Sanuwave Health, Inc., a Nevada corporation (the “Company”), dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm, and notified Baker Tilly US, LLP (“Baker Tilly”) of its formal decision to engage Baker Tilly to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective beginning with the review of the Company’s conden…
Results of Operations and Financial Condition. On May 9, 2025 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2025. As previously announced, a business update via conference call will occur on May 9, 2025 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), the former independent registered public accounting firm of Sanuwave Health, Inc., a Nevada corporation (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 10, 2025. On April 10, 2025, Marcum resigned as the Company’s independent…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. Effective March 27, 2025, Sanuwave, Inc., a wholly owned subsidiary of Sanuwave Health, Inc. (the “Company”), entered into a lease for the Company’s new headquarters in Eden Prairie, Minnesota (the “Lease”). Pursuant to the Lease, Sanuwave Inc. is obligated to pay monthly base rent of $21,687.25, which increases annually by 3.5%, plus its pro rata share of property taxes and operating expenses. The Lease has a term of 60 months and includes one opti…
Results of Operations and Financial Condition. On March 21, 2025 , Sanuwave H ealth, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. As previously announced, a business update via conference call will occur on March 21, 2025 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors. The information in this
Other Events. On March 3, 2025, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC approving the Uplisting. The Company expects its Common Stock will begin trading on Nasdaq on March 7, 2025 under the ticker symbol “SNWV.” Forward-Looking Statements This Current Report on Form 8-K may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to the expected timing…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on January 3, 2025, Timothy Hendricks separated from service as Executive Vice President of Sales of Sanuwave Health, Inc. (the “Company”), effective as of the same date. In connection with his separation, Mr. Hendricks and the Company entered into a Separation and Release Agreement, dated January 13, 2025 (the “Severance A…
Importance-ranked changes since the prior daily snapshot.
Valuation rose by 13.6 points (from 30.3 to 43.9).
Valuation label changed from 'expensive' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.